The safety, plasma pharmacokinetics, and antiviral activity of T-20 were assessed in a randomized, multicenter, open-label phase 2 clinical trial. T-20 is a 36-amino acid peptide that blocks de novo infection and cell-to-cell virus transmission by inhibiting gp41-mediated fusion. 78 patients with plasma HIV RNA values >5,000 copies/ml on a background of either stable or no ARV therapy were assigned to 6 groups representing T-20 doses ranging from 12.5 to 200 mg/day. T-20 was given by continuous subcutaneous infusion or by b.i.d. subcutaneous injection for 28 days. At entry, mean plasma HIV-RNA was 5.0 log10 copies/ml and mean CD4+ count was 117 cells/mm3. 77 of 78 patients reported antiretroviral experience (mean number of prior ARV's=9) and 98% were protease inhibitor experienced (mean number of prior PI's=3). T-20 was well tolerated at all doses throughout the 28-day treatment period. No treatment-related Grade 3 or 4 systemic toxicities were observed. Two patients withdrew due to AE's. Induration and erythema at the site of infusion or injection were seen in most patients. Sustained steady-state plasma concentrations of T-20 (peak-to-trough ratio <2) were observed both for administration by continuous infusion and by twice-daily injection. A dose-related suppression of plasma HIV RNA was observed. The average maximum change from baseline ranged from -0.3 to 1.6 log10 copies/mL across the treatment groups. The magnitude and durability of viral load suppression was greated in patients with baseline viral load <100,000 copies/mL. T-20 represents the first member of a safe and potent new class of antiretroviral agents that inhibit the function of gp41. Further studies to assess the long-term safety and durability of T-20 in combination therapy are in progress.
| Aboud, Katherine S; Barquero, Laura A; Cutting, Laurie E (2018) Prefrontal mediation of the reading network predicts intervention response in dyslexia. Cortex 101:96-106 |
| Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6 |
| Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521 |
| Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168 |
| Robert BraĊĦi?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6: |
| Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866 |
| AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786 |
| Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671 |
| Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72 |
| Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608 |
Showing the most recent 10 out of 1014 publications
